(HealthDay)—Technivie (ombitasvir, paritaprevir and ritonavir) has been approved by the U.S. Food and Drug Administration, in tandem with ribavirin, to treat hepatitis C genotype 4 infection among people without poor liver ...
Jul 25, 2015
0
13
(Medical Xpress)—One of the most challenging problems in biology is the extreme difficulty in predicting phenotype from genotype – and the questions it creates: If we could rear genetically identical individuals from ...
The fixed-dose drug combination ombitasvir/paritaprevir/ritonavir (trade name Viekirax) has been available since January 2015 for the treatment of adults with chronic hepatitis C infection. The German Institute for Quality ...
May 28, 2015
0
8
The drug dasabuvir (trade name Exviera) has been available since January 2015 for the treatment of adults with chronic hepatitis C infection. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined ...
May 20, 2015
0
16
The way the brain responds while sipping a delicious milkshake can predict who will gain weight and who will not—but only if the individual has just eaten and has a certain genetic profile, a new brain imaging study by ...
May 20, 2015
1
54
In two studies appearing in the May 5 issue of JAMA, patients with chronic hepatitis C virus (HCV) genotype 1 infection and with or without cirrhosis achieved high rates of sustained virologic response after 12 weeks of treatment ...
May 5, 2015
0
20
Results presented today at The International Liver Congress 2015 show that the sofosbuvir (SOF)/daclatasvir (DCV) treatment combination is effective amongst hepatitis C virus (HCV) genotype-1 mono-infected patients. These ...
Apr 25, 2015
0
6
Once-daily oral grazoprevir/elbasvir combination therapy, taken without interferon or ribavirin for 12 weeks, demonstrated high sustained virologic response rates for treatment-naïve patients with cirrhotic or non-cirrhotic ...
Apr 24, 2015
0
9
Results presented today at The International Liver Congress 2015 show that a 12-week oral regimen of once-daily single tablet grazoprevir/elbasvir (GZR/EBR) is effective and well-tolerated in treatment-naive (TN) patients ...
Apr 24, 2015
0
4
Phase III results revealed today at The International Liver Congress 2015 show that once-daily treatment with daclatasvir (DCV) plus sofosbuvir (SOF) resulted in an overall 97% sustained virologic response (SVR) at 12 weeks ...
Apr 23, 2015
0
11
